Lexaria engages InClin as CRO for Phase 1b hypertension study; budget $1.4M

Lexaria Bioscience Corp.

Master Services Agreement with InClin for FDA-registered Phase 1b hypertension study HYPER-H23-1 using DehydraTECH-powered cannabidiol.
Initial work order budget $1,395,000; includes $72,355 (10% direct costs) and $335,242 (50% pass-through costs).
Financing of at least US$1,000,000 completed, making the work order definitive.
Both MSA and work order can be terminated with or without cause on 30 days' notice.
Kick-off meeting between Lexaria and InClin scheduled for late May 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.